

## Supplementary Figure S1




Figure S1. EC<sub>50</sub> values of Src inhibitors estimated by the BSR reporter and Western blot. (A) EC<sub>50</sub> of dasatinib for Src activity inhibition calculated with BSR reporter, by setting the normalized luciferase activity of the vehicle control as 0% and the maximum increased activity of drug treatments as 100%. (B) EC<sub>50</sub> of dasatinib for Src activity inhibition estimated by the relative band intensities (% of vehicle control) of Western blot using phospho-Src antibodies. (C) EC<sub>50</sub> of saracatinib for Src activity inhibition estimated by BSR reporter. (D) EC<sub>50</sub> of saracatinib for Src activity inhibition estimated by Western blot.